Psoriasis im JDDG
64 Artikel in dieser Kategorie
-
Background and objectives Biologic therapies for psoriasis have shown promise in reducing the risk of Psoriatic Arthritis (PsA) by targeting inflammatory pathways. Emerging evidence suggests that phototherapy may also exert systemic anti-inflammatory effects. This study examines the impact of phototherapy on the progression to PsA.Patients and methods This exploratory, hypothesis generating retrospective cohort study comprised 667 psoriatic patients, subclassified based on therapeutic interventi
- 48 Aufrufe
-
No abstract supplied.Weiterlesen
- 49 Aufrufe
-
Non-invasive imaging techniques allow a quick and easy in vivo examination of the skin with different penetration depths and resolution depending on the applied technology. Established methods such as dermoscopy and high-resolution sonography of the skin have been an integral part of everyday life for decades. Additionally, new emerging techniques such as optical coherence tomography (OCT), reflectance confocal microscopy (RCM), and line-field confocal OCT (LC-OCT) have entered clinical practice
- 42 Aufrufe
-
No abstract supplied.Weiterlesen
- 69 Aufrufe
-
Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non-professional activities. This study investigates the effects of long-term treatment with adalimumab regarding work ability, non-professional activities, and health-related quality of life in a large real-word population in Germany.Patients and methods Single-arm, multicenter non-interventional study to document routine care data for up to 5 years in adult patien
- 52 Aufrufe
-
Background and objectives Preventive tuberculosis (TB) therapy before initiating MTX or IL-17/IL-23/IL-12/23p40 inhibitors for latent tuberculosis infection (LTBI) is supported by indirect evidence of TB reactivations with TNF inhibitors. However, direct evidence for MTX or IL-17/IL-23/IL-12/23p40 inhibitors is limited. To better evaluate the risk of TB reactivation, data on LTBI patients exposed to these medications without preventive TB therapy are necessary. This study was conducted as part o
- 53 Aufrufe
-
Noninvasive imaging of skin diseases is highly valued in both dermatological research and practice. Reflectance confocal microscopy (RCM) is primarily applied to assess melanocytic lesions because of its high resolution, whereas optical coherence tomography (OCT) is particularly used for non-melanocytic skin tumors owing to its greater penetration depth. Line-field confocal optical coherence tomography (LC-OCT) combines the techniques of reflectance confocal microscopy (RCM) and optical coherenc
- 49 Aufrufe
-
No abstract supplied.Weiterlesen
- 57 Aufrufe
-
No abstract supplied.Weiterlesen
- 152 Aufrufe
-
No abstract supplied.Weiterlesen
- 156 Aufrufe
-
No abstract supplied.Weiterlesen
- 66 Aufrufe
-
Background and objectives Atopic dermatitis (AD) and psoriasis (Pso) are frequently associated with psychological distress. This study evaluated the prevalence and correlates of shame-related disorders (SRD), namely body dysmorphic disorder (BDD) and social anxiety disorder (SAD), in patients with AD and Pso.Patients and methods A monocentric, cross-sectional study was conducted in adult patients from 07/2023 to 03/2024. A trained clinical psychologist assessed subjects for BDD and SAD. Addition
- 91 Aufrufe
-
No abstract supplied.Weiterlesen
- 208 Aufrufe
-
Background and objectives Improved understanding of the immunopathogenesis of psoriasis has led to the development of effective targeted therapies, but patients who respond to treatment without total skin clearance have residual disease. The aim of this study was to demonstrate the existence of specific residual disease (or residual PASI) anatomical localizations related to different biologic agents.Methods and patients This retrospective, observational, multi-center study analyzed clinical data
- 98 Aufrufe
-
No abstract supplied.Weiterlesen
- 173 Aufrufe
-
No abstract supplied.Weiterlesen
- 195 Aufrufe
-
Background and objectives Mycosis fungoides (MF) accounts for the majority of cutaneous lymphomas (CL). There is a documented delay in the diagnosis of early-stage MF. However, its timely diagnosis is paramount to avoid potentially harmful therapies and undue patient distress. The aim of this study was to examine and compare the views held by both specialists and non-specialists in CL regarding the diagnosis of early-stage MF, to identify clinical needs.Methods Two distinct questionnaires were d
- 88 Aufrufe
-
Used since 2011 in the USA and 2012 in the EU, Janus kinase inhibitors (JAKi) are gaining increasing acceptance as a treatment for dermatological diseases such as atopic dermatitis, psoriasis, psoriatic arthritis, alopecia areata, chronic hand eczema and vitiligo. Knowledge of their mechanism of action and potential side effects is necessary for a safe and effective use. Their short half-life requires daily administration, enables good controllability and is appreciated by many patients due to t
- 91 Aufrufe
-
No abstract supplied.Weiterlesen
- 304 Aufrufe
-
Background There are only limited histomorphological data on the response of psoriatic skin lesions to topical dithranol. In vivo reflectance confocal microscopy (RCM) in psoriatic skin is highly correlated with histopathological findings and allows non-invasive monitoring of treatment effects on a cellular level.Patients and methods Prospective, single-center pilot study at a university-based clinic of dermatology between January 1st and August 30th, 2016. Psoriatic lesions of 20 patients recei
- 209 Aufrufe
-
No abstract supplied.Weiterlesen
- 346 Aufrufe
-
No abstract supplied.Weiterlesen
- 183 Aufrufe
-
Background The pathogenesis of nummular eczema (NE) remains unclear, and no targeted therapy has been approved. Apremilast is a small molecule inhibitor targeting phosphodiesterase-4.Patients and methods A phase IIb randomized, double-blind, placebo-controlled study evaluating the effects of apremilast or placebo in patients with NE. Patients received apremilast (30 mg BID) or placebo until week 16 followed by an open label phase in which all patients were treated with apremilast until week 32.
- 202 Aufrufe
-
No abstract supplied.Weiterlesen
- 176 Aufrufe
-
No abstract supplied.Weiterlesen
- 160 Aufrufe